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Anticoagulant-related nephropathy is a type of acute
kidney injury caused by overcoagulation. We describe a
case of an 84-year-old man with arterial hypertension,
coronary heart disease and atrial ﬁbrillation treated with
acenocoumarol, who presented with haematoproteinuria
and acute kidney injury during a phase of excessive
anticoagulation. In addition to IgA nephropathy, renal
biopsy also revealed acute tubular necrosis, red blood
cell casts and positive iron staining in tubular cells. After
this acute episode, renal function improved and
proteinuria decreased below the nephrotic range.
BACKGROUND
Anticoagulant therapy has a central role in diseases
with thromboembolic events, such as atrial ﬁbrilla-
tion and deep vein thrombosis.1 Acenocoumarol is
a vitamin K antagonist with similar efﬁcacy as war-
farin in the treatment of venous and arterial
thromboembolism.2 Closely monitoring of inter-
national normalised ratio (INR) is essential to avoid
overcoagulation, because there is a large interindivi-
dual variability of dose requirements. In the past
years, there has been recognised an association
between overcoagulation and acute kidney injury
(AKI), named as anticoagulant-related nephropathy
(ARN), ﬁrst described with warfarin and, because
of this, is also called warfarin-related nephropathy
(WRN). We report a case of a patient with under-
diagnosed IgA nephropathy, presenting with AKI
due to overcoagulation with acenocoumarol.
CASE PRESENTATION
An 84-year-old patient presented with gross haema-
turia, fatigue and shortness of breath. He had a
medical history of arterial hypertension for 10 years
and coronary heart disease (the patient underwent
triple coronary artery bypass grafting 10 years ago).
He also had atrial ﬁbrillation, with a pacemaker
implanted 3 years ago, and is under oral anticoagu-
lation with acenocoumarol (CHADS2-VASc score
was 4). His medical history included prostate adeno-
carcinoma diagnosed in the year before (stage 1;
T1cN0M0, according to prostate cancer staging of
American Joint Committee on Cancer). The patient
also had well-controlled hypothyroidism. His
medical history was signiﬁcant for bone tuberculosis
at the age of 18, resolved without major sequelae.
Medications included ramipril plus hydrochlor-
othiazide, levothyroxine, acenocoumarol, esome-
prazole, amlodipine, tamsulosin, bicalutamide and
goserelin.
On admission his blood pressure was 123/
72 mm Hg, pulse rate was 92 bpm, temperature
36.8°C and oxygen saturation 98% on room air.
Physical examination revealed crackles in the lung
bases and 2+ pitting oedema in both lower
extremities.
INVESTIGATIONS
Laboratory studies showed haemoglobin of 10.8 g/
dL with normal leucocyte and platelet counts.
Serum creatinine (SCr) was 4.68 mg/dL, glomerular
ﬁltration rate was 12 mL/min/1.73 m2, estimated by
Modiﬁcation of Diet in Renal Disease (MDRD)
formula, and blood urea nitrogen was 82 mg/dL,
with normal electrolytes. Serum albumin was low
(32 g/L). The prothrombin time was 23.3 s and
INR 2.03, but 1 week before this evaluation his
INR was 6.96. Urinalysis revealed proteinuria
(3.6 g/24 hour) and erythrocyturia (3394/μL). No
abnormalities were noted on renal ultrasound scan.
Analysing the blood tests and the urinalysis from
the year before, we found that the patient had
normal renal function in the previous month (SCr
1.0 mg/dL) and erythrocyturia was present in the
past 2 years, but proteinuria was only noticed in
this episode. Autoimmune markers including anti-
neutrophil cytoplasmic antibody, antiglomerular
basement membrane antibody and antinuclear anti-
body were negative. C3 and C4 levels were normal.
Serum and urine immunoﬁxation were negative for
monoclonal gammopathy.
A renal biopsy was performed. The biopsy speci-
men contained 16 glomeruli with mild mesangial
hypercellularity. The interstitium was oedematous
with the presence of diffuse acute tubular necrosis
and occlusive red blood cell (RBC) casts (ﬁgure 1).
The arteries had severe intima thickness (ﬁgure 1).
The immunoﬂuorescence revealed mesangial depos-
its of IgA (+++), C3 (+++) and light chains κ
and λ (++; ﬁgure 2). The histology ﬁndings
allowed to diagnose two conditions: (1) ARN; (2)
IgA nephropathy (M1E0S0T0, according with
Oxford Classiﬁcation of IgA nephropathy).
TREATMENT, OUTCOME AND FOLLOW-UP
Ramipril plus hydrochlorothiazide and acenocou-
marol were withdrawn. INR was normalised and,
at this time, enoxaparin 60 mg once daily was
started. His renal function slowly improved and the
patient was discharged with SCr 3.45 mg/dL. Two
months later his SCr decreased to 2.7 mg/dL, but
proteinuria remained in the nephrotic range (4.6 g/
24 hour). Thus, enalapril 5 mg once daily was pre-
scribed and enoxaparin was replaced by a new oral
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anticoagulant: apixaban 2.5 mg two times a day. Eleven months
later, his SCr continued to decrease to 1.7 mg/dL and protein-
uria markedly improved (400 mg/24 hour). However, signiﬁcant
erythrocyturia (840/μL) was still present, although without more
episodes of gross haematuria.
DISCUSSION
ARN is deﬁned as AKI without obvious aetiology in the setting
of an INR of >3.0,3 accompanied by microscopic or gross
haematuria.3
Previous reports on ARN focused on anticoagulation with
warfarin and acenocoumarol;4 however, recent case reports
suggest that it can also occur with new oral anticoagulants.5–7
ARN is an underdiagnosed condition for the reason that
nephrologists are reluctant to perform renal biopsy in patients
under anticoagulation therapy, because of concerns related to
the risk of thrombosis/thromboembolism while anticoagulation
is withheld and the risk of bleeding when the anticoagulation is
restarted. Thus, most of cases have a presumptive diagnosis,
being difﬁcult to determine the real incidence of ARN.
Morphologically, ARN is characterised by glomerular haemor-
rhage and tubular obstruction by RBC casts, causing acute and
chronic tubular damage, predominantly in distal nephron seg-
ments. The glomeruli show little or no abnormalities by light,
immunoﬂuorescence or electron microscopy.8
To best of our knowledge, three cases of ARN in patients
with IgA nephropathy have been reported: two cases occurred
in patients treated with dabigatran6 7 and one in a case of antic-
oagulation with warfarin.9 Patients with chronic kidney disease
are particularly susceptible, but there are other underlying risk
factors, such as age, diabetes and diabetic nephropathy, arterial
hypertension, glomerulonephritis and heart failure.10 In this
case, the presence of proteinuria in nephrotic range raised the
suspicion that an underlying glomerulopathy might also be
present, which gave an indispensable role to the renal biopsy to
ensure a correct diagnosis. In IgA nephropathy, glomerular
haemorrhage leads to a tubular injury but, in our patient, we
assumed that haematuria as a consequence of IgA nephropathy
as a minor role in the development of AKI. One study showed
that only few patients (<1.5%) with IgA nephropathy and gross
haematuria had evidence of AKI, which leads to think that
other mechanisms may be involved.11 Thrombin, a vitamin
K-dependent coagulation factor stimulates signalling cascades,
binds and activates a family of proteinase-activated receptors
(PARs) expressed in endothelial cells.12 It is suggested that acti-
vation of PARs is important to maintain endothelial integrity
(including in glomeruli), and the reduction in thrombin levels
caused by anticoagulants affects the endothelial permeability,
allowing glomerular bleeding. Recently, one study showed that
activated protein C signalling has trophic and antiapoptotic
effects in cultured podocytes. It is demonstrated that in patients
treated with vitamin K antagonists the levels of protein C acti-
vated are decreased, and thus, it is another possible pathway of
glomerular injury by these drugs.13
In this case, the patient had prostate cancer, which is a
reported cause of haematuria. Nevertheless, we assumed that
haematuria had, mainly, a glomerular origin, since RBC casts
were found on renal biopsy.
The glomerular lesions concerning IgA nephropathy were
mild (M1E0S0T0, according with Oxford Classiﬁcation of IgA
nephropathy), but the tubulointerstitial involvement was more
evident with acute tubular necrosis, extensive RBC casts and
positive iron staining in the cytoplasm of proximal tubular cells
(ﬁgure 3). The mechanism of iron tubular toxicity seems to be
related with oxidative stress.14 In high concentrations, free
haemoglobin released by RBCs in the tubular lumen is uptaken
via the megalin-cubulin receptors and the haeme molecule
causes oxygen-radical formation, increasing lipid peroxidation
and denaturation of proteins, which leads to apoptosis.14
Haeme also induces mitochondrial injury through oxidative
damage and augments ischaemia-induced peroxidation.15
In our case, in addition to hypertension, cardiovascular
disease and age, the presence of IgA nephropathy appears to be
Figure 2 Immunoﬂuorescence microscopy demonstrating granular
mesangial deposits of IgA (×400).
Figure 3 Iron in cytoplasm of tubular epithelial cells. Perls Prussian
blue staining. Exuberant red blood cells casts are also noted (×400).
Figure 1 Red blood cells casts and acute tubular necrosis. It also
showed an artery with marked intima thickness. Masson’s trichrome
staining (×400).
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a predisposing factor to ARN. Renal function was normal prior
to this episode of AKI, which is according with histological ﬁnd-
ings. Beyond severe intima thickness of arteries due to hyperten-
sion, there were no signs of chronic damage on renal biopsy,
such as glomerulosclerosis, tubular atrophy and interstitial ﬁbro-
sis. In glomeruli, the presence of mild mesangial hypercellularity
was the only change noticed. Thus, in this case, we assume that
AKI is explained mostly by ARN and its acute tubulointerstitial
involvement, in a background of IgA nephropathy. At previous
evaluation, the proteinuria signiﬁcantly decreased (400 mg/
24 hour) as a consequence of enalapril, and renal function
markedly improved (SCr 1.7 mg/dL). Owing to good response
to therapy—proteinuria below 1 g/24 hour—the patient was not
submitted to any additional treatment (like steroids) for IgA
nephropathy.
Treatment of this condition is mainly supportive and includes
the returning of INR to a therapeutic range. N-acetylcysteine,
by its antioxidant effect, has been shown to prevent AKI in
animal models of WRN.16 Steroids are not recommended and
were used with success only in one case.7 The most important
therapeutic approach is the prevention and early detection of
ARN, maintaining INR in the therapeutic range and closely
monitoring renal function, even in patients treated with new
oral anticoagulants.
In most patients with ARN, renal function stabilises or
improves slightly within the ﬁrst few weeks.8 In our case, renal
function, which was normal before this episode of AKI, was
consistently improving and proteinuria decreased. Histologically,
the absence of glomerulosclerosis and tubulointerstitial ﬁbrosis
are markers of good renal prognosis. The only histological
marker of poor renal prognosis is the severe intima thickness of
arteries according to the medical history of hypertension. In
addition to renal prognosis, which appears to be favourable, the
vital prognosis will be affected by patient’s multiple comorbid-
ities and, inclusively, by ARN. In one study of 4006 patients,
presumptive ARN has been associated with an increase in mor-
tality independent of age, sex, race, haemorrhage, atrial ﬁbrilla-
tion, heart failure and diabetes mellitus.10
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Learning points
▸ Anticoagulant-related nephropathy is a type of acute kidney
injury caused by overcoagulation with vitamin K antagonists
of other anticoagulants.
▸ The risk of occurrence of this condition is higher in patients
with diabetes, hypertension, heart failure, chronic kidney
disease and glomerulonephritis.
▸ Since the renal biopsy is not performed in most cases, the
diagnosis is frequently presumptive.
▸ Morphologically, it is characterised by glomerular
haemorrhage and acute tubular necrosis due to obstruction
by red blood cell casts and, ultimately, by haeme toxicity.
▸ Treatment is mainly supportive and the central approach is
prevention, closely monitoring the patients under
anticoagulation.
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